Meropenem Kabi (Meropenem Anhydrous)

Meropenem inhibits bacterial cell wall synthesis by binding to penicillin‑binding proteins. This prevents the final cross‑linking step of peptidoglycan formation, causing cell wall weakness, osmotic lysis, and bacterial death. Its stability against most β‑lactamases gives it activity against many resistant pathogens.

The prescribed dose is set by the treating clinician based on the type and severity of infection, the patient’s age, weight, and renal function. Adjustments are required for impaired kidney function, and the dosing interval may be modified for continuous or extended infusions as directed by the prescriber.

Data on Meropenem use during pregnancy and lactation are limited. It should be prescribed only when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should discuss the risk‑benefit profile with the patient and consider alternative therapies when appropriate.

To place an order, submit an enquiry on the Meropenem Kabi product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team then provides pricing, availability, shipping details (including cold‑chain handling if needed), and assists with import documentation.

Meropenem shares a similar spectrum with other carbapenems such as imipenem‑cilastatin and ertapenem, but it offers broader activity against Pseudomonas aeruginosa and certain resistant Gram‑negative organisms. Unlike ertapenem, which lacks activity against Pseudomonas, Meropenem is often preferred for severe hospital‑acquired infections requiring potent anti‑Pseudomonal coverage.

Meropenem Kabi should be stored at 2‑8 °C in a refrigerator, protected from light. The product must remain in its original packaging to prevent moisture exposure. Do not freeze or shake the vial; reconstitute only immediately before intravenous administration according to the manufacturer’s instructions.

Meropenem Kabi is supplied as a sterile powder for injection. It is reconstituted with the appropriate diluent and administered intravenously over a 15‑ to 30‑minute infusion, or as an extended infusion if clinically indicated. Administration should be performed by qualified healthcare personnel in a setting equipped for aseptic preparation.

The most serious adverse events include seizures, especially in patients with renal impairment or pre‑existing CNS disorders; severe hypersensitivity reactions such as anaphylaxis; and Clostridioides difficile‑associated colitis, which can lead to life‑threatening diarrhea. Prompt recognition and medical intervention are essential if these events occur.

Meropenem Kabi is contraindicated in individuals with a known hypersensitivity to meropenem, other carbapenems, or any β‑lactam antibiotics. Caution is also advised for patients with a history of seizures, severe renal impairment without dose adjustment, or those receiving concomitant valproic acid without appropriate monitoring.